Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia

Michael W Boyer, MD, Sonali Chaudhury, MBBS,MD, Kara L Davis, DO, Timothy Alan Driscoll, MD, Stephan A Grupp, MD PhD, Michelle Hermiston, MD PhD, Samuel John, MD, Amy K Keating, MD PhD, Christina Kovacs, BS, JD, Andrea Magley, BS, Gary Douglas Myers, MD, Christine L Phillips, MD, Michael A Pulsipher, MD, Das Purkayastha, PhD, Julie-An Talano, MD, Jennifer Willert, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136340

Published: 2020

Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker

Blood (2019) 134 (Supplement_1): 665.

https://doi.org/10.1182/blood-2019-124716

Published: 2019

Journal Articles

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

Fuad A El Rassi, MD, Deepika S. Darbari, MD, Arthur Burnett, MD MBA, Jincy Paulose, MD, Dramane I Laine, Das Purkayastha, PhD, Gregory J Kato, MD

Blood (2019) 134 (Supplement_1): 1007.

https://doi.org/10.1182/blood-2019-125790

Published: 2019

Journal Articles

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Richard Thomas T. Maziarz, MD, Mrinal M. Patnaik, MDMBBS, Bart L Scott, MD, Sanjay R. Mohan, MD MSCI, Abhinav Deol, MD, Scott D. Rowley, MD, Dennis Kim, MD, Kelly Haines, Gaetano J Bonifacio, MD, Patrice Rine, Das Purkayastha, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 662.

https://doi.org/10.1182/blood-2018-99-113582

Published: 2018

Journal Articles

Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy: Update from the Radius-X Midostaurin Expanded Access Program

Alexander E. Perl, MD, Kendra L. Sweet, MD, Gail J. Roboz, MD, Stephen A. Strickland, MD, Mark R. Litzow, MD, Gaetano J Bonifacio, MD, Kelly Haines, Alysha Barbera, Das Purkayastha, Andrew Dalovisio, MD

Blood (2018) 132 (Supplement 1): 4038.

https://doi.org/10.1182/blood-2018-99-113608

Published: 2018

Journal Articles

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Nirmish Shah, Ralph Boccia, Walter K. Kraft, Brandon M. Hardesty, Jincy Paulose, Dram Laine, Das Purkayastha, Savita Nandal, Abdullah Kutlar, MD

Blood (2018) 132 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2018-99-111332

Published: 2018

Journal Articles

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Gail J. Roboz, MD, Stephen A. Strickland, MD MSCI, Mark R. Litzow, MD, Andrew Dalovisio, MD, Alexander E. Perl, MD, Gaetano Bonifacio, MD, Kelly Haines, Alysha Barbera, Das Purkayastha, Kendra Sweet, MD

Blood (2017) 130 (Supplement 1): 1338.

https://doi.org/10.1182/blood.V130.Suppl_1.1338.1338

Published: 2017

Journal Articles

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

Ellen K Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Javier Pinilla-Ibarz, MD PhD, Michael W. Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, MD, Michael R. Savona, MD, Ilva Dautaj, MS, Das Purkayastha, Karen Habucky, PhD, Michael J. Mauro, MD

Blood (2017) 130 (Supplement 1): 2875.

https://doi.org/10.1182/blood.V130.Suppl_1.2875.2875

Published: 2017

Journal Articles

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector, Francisco Cervantes, Ricardo Pasquini, Nelma Cristina D. Clementino, Pedro Enrique Dorlhiac Llacer, Anthony P. Schwarer, Francois-Xavier Mahon, Delphine Rea, Susan Branford, Das Purkayastha, LaTonya Collins, Tomasz Szczudlo, Brian Leber

Blood (2014) 124 (5): 729–736.

https://doi.org/10.1182/blood-2013-12-544015

Published: 2014

Journal Articles

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Nelson Spector, MD, PhD, Brian Leber, MD, Ricardo Pasquini, MD, PhD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Gabriel Etienne, MD, PhD, Agnès Guerci-Bresler, MD, Susan Branford, PhD, Das Purkayastha, LaTonya Collins, BSN, Tomasz Szczudlo, Francisco Cervantes, MD, PhD

Blood (2012) 120 (21): 694.

https://doi.org/10.1182/blood.V120.21.694.694

Published: 2012

NARROW

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy: Update from the Radius-X Midostaurin Expanded Access Program

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only